The combination of anti-programmed death-ligand 1 antibody atezolizumab and anti-VEGF antibody bevacizumab has revolutionized systemic therapy for unresectable HCC, which represents the majority of primary liver cancer. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.